Drug pipeline
Explore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The Poliovirus type 2 capsid D-antigen is the native, immunogenic form of the viral protein shell required for the induction of protective neutralizing antibodies. It consists of an icosahedral arrangement of 60 copies each of the structural proteins VP1, VP2, VP3, and VP4, which encapsulate the viral RNA genome. The D (dense) state is characterized by its ability to bind to the poliovirus receptor (CD155) and its high stability compared to the C (coreless) antigen, which represents a non-infectious, altered conformation. In the context of vaccine development, the D-antigen is the critical component of the Inactivated Poliovirus Vaccine (IPV), where its concentration is measured in D-antigen units (DU) to ensure potency. Therapeutic and prophylactic strategies focus on maintaining these specific epitopes to elicit a robust immune response, as the loss of D-antigenicity results in a significant reduction in vaccine efficacy.
Induction of neutralizing antibodies that bind to the D-antigen epitopes to prevent viral attachment and entry into host cells.
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Poliovirus type 2 capsid D-antigen (PV2 D-antigen).